MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.5x | −0.3x | −0.6x | |
PEG Ratio | 1.26 | 0.00 | 0.00 | |
Price/Book | 10.6x | 0.3x | 2.6x | |
Price / LTM Sales | 9.4x | 0.6x | 3.1x | |
Upside (Analyst Target) | 69.5% | 90.5% | 56.1% | |
Fair Value Upside | Unlock | 12.9% | 7.8% | Unlock |